Skip to main
XRAY

DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

DENTSPLY SIRONA (XRAY) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 64%
Sell 9%
Strong Sell 0%

Bulls say

Dentsply Sirona has demonstrated strong revenue growth across various segments, with orthodontics posting a double-digit percentage increase and essential dental solutions generating $372 million in sales, reflecting a 7.8% rise on a reported basis. Furthermore, Wellspect Healthcare showcased significant performance with reported revenue increases of 15.6% and 6.9% during different reporting periods, indicating robust demand for their products. Additionally, sales growth in Europe at 9.9% underscores the company's expanding market presence and resilience in a competitive landscape.

Bears say

Dentsply Sirona has revised its sales outlook downward, now anticipating a decline of 4% to 5% in constant currency, compared to a previous estimate of 2% to 4%. The company's gross margin is expected to decrease by 160 basis points in Q3 2025 relative to the same period in 2024, along with a projected drop in adjusted EBITDA margins to 17.5% for 2026, down from 18.1% in 2025. Additionally, revenues from its connected technology solutions segment have reported a decline, compounded by pressure in its orthodontics and implants segment, particularly due to challenges associated with the Byte clear aligner offering.

DENTSPLY SIRONA (XRAY) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 64% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DENTSPLY SIRONA (XRAY) Forecast

Analysts have given DENTSPLY SIRONA (XRAY) a Hold based on their latest research and market trends.

According to 11 analysts, DENTSPLY SIRONA (XRAY) has a Hold consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DENTSPLY SIRONA (XRAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.